Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Serina Therapeutics, Inc. (SER)

Serina Therapeutics Q2 net loss widens to $8.9 million; SER-252 cohort 1 dosing done

Mixed Impact 3 of 5 earnings Written later

Serina Therapeutics reported second quarter 2026 results with a net loss attributable to common shareholders of $8.9 million, up from $6.6 million a year earlier, while the per-share loss narrowed to $(0.55) from $(0.66) on a larger share count. The company said it completed enrollment and dosing in Cohort 1 of the SER-252 Phase 1b registrational study in July 2026, ahead of its prior guidance, with top-line data still targeted for the first half of 2027.

Key points

  • Net loss attributable to common shareholders was $8.9 million, or $(0.55) per share, for Q2 2026, versus $6.6 million, or $(0.66) per share, for Q2 2025.
  • No revenue was reported in Q2 2026, compared with $130 thousand in Q2 2025; total operating expenses rose to $6.8 million from $5.7 million.
  • Cash and cash equivalents totaled $23.0 million as of June 30, 2026.
  • Cohort 1 of SER-252 completed enrollment and dosing in July 2026, ahead of guidance for the end of Q3 2026; top-line data are targeted for the first half of 2027.

The filing

CompanySerina Therapeutics, Inc. (SER)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:05 PM ET
Accession number0001708599-26-000048

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.